Document is current
Any future updates will be listed below
-
Authors
Zhao, Qiannan
Cao, Hengyi
Zhang, Wenjing https://orcid.org/0000-0002-2046-3948
Li, Siyi
Xiao, Yuan https://orcid.org/0000-0001-8152-5068
Tamminga, Carol A. https://orcid.org/0000-0002-6366-5697
Keshavan, Matcheri S.
Pearlson, Godfrey D.
Clementz, Brett A.
Gershon, Elliot S. https://orcid.org/0000-0003-4818-8631
Hill, Scot Kristian
Keedy, Sarah K. https://orcid.org/0000-0002-2139-9271
Ivleva, Elena I.
Lencer, Rebekka
Sweeney, John A. https://orcid.org/0000-0003-1752-2828
Gong, Qiyong
- License Information
-
More Information
Article History
Received: 14 May 2021
Revised: 28 January 2022
Accepted: 19 February 2022
First Online: 8 March 2022
Competing interests
: WZ, SYL, and JAS consulted to VeraSci. CAT has served on the advisory board for drug development for Intra-Cellular Therapies, Inc., as an ad hoc consultant for Eli Lilly, Sunovion, Astellas, Pfizer, and Merck, has been a council member and unpaid volunteer for the National Alliance on Mental Illness, and served as deputy editor for the American Psychiatric Association. MSK has received research support from Sunovion and GlaxoSmithKline. The remaining authors declare no competing interests.
